NCT07278648尚未招募不适用
Prescription of High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department. Retrospective Cohort Study
Consorci Sanitari de l'Alt Penedès i Garraf1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2026年2月5日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Hemorragic event
研究概览
简要总结
This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes:
- •B01AA - Vitamin K antagonists: warfarin and acenocoumarol
- •B01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, …
- •B01AE - Direct thrombin inhibitors: dabigatran
- •B01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban
排除标准
- •Those who are not part of the CSAPG healthcare area.
- •Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.
结局指标
主要结局
Hemorragic event
时间窗: Day 90 from baseline
Proportion of patients who experience a hemorrhagic event within 90 days of hospital discharge
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial (The PANART trial)2023-509022-22-00Akershus University Hospital744
已完成
不适用
Prescribing Appropriateness of Thrombo-prophylaxis in Intensive Care Unit of Tertiary HospitalDVTNCT06539156Ain Shams University400
招募中
4 期
Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in non-atrial fibrillation patients after transcatheter aortic valve implantation: a pragmatic, international, multicentre, randomized clinical trial (POPular ATLANTIS trial)2023-504637-42-01St Antonius Hospital1,950
招募中
2 期
Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect2024-517115-70-00Sint Antonius Ziekenhuis Stichting52
招募中
不适用
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic MalignanciesLymphomaLeukemiaNCT07270263Medical University of Gdansk100